Collection and Analysis of the Clinical and Biological Characteristics of Patients Treated for Giant Cells ARTEitis (Horton's Disease)
- Conditions
- Giant Cell ArteritisHorton Disease
- Registration Number
- NCT04142515
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Brief Summary
Giant cell arteritis (GCA) or Horton's disease: frequent large vessel vasculitis (cephalic) (incidence estimated at 9 per 100,000 in France), potentially responsible for blindness.
Treatment: corticosteroid therapy, which is effective in the vast majority of cases.
Clinical problem: relapse; 36% to 44% of patients have a relapse that occurs in the first year for many patients, requiring a re-escalation of corticosteroid therapy, with its consequences:
* Cumulative dose of corticosteroid therapy that causes cardiovascular and infectious morbidity.
* Requires additional immunosuppressive treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 83
- Patients aged 45 years or older
- Patients with giant cell arteritis according to ACR criteria or revised criteria incorporating imaging parameters,
- Patients managed at the University Hospital of Carémeau in Internal Medicine from 01/01/2011 to 01/01/2020.
None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical and paraclinical characteristics of patients diagnosed with ACG day 1 Describe the clinical and paraclinical characteristics of patients diagnosed with ACG to determine whether certain characteristics are significantly associated with a higher risk of developing corticosteroid dependence
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHUNimes
🇫🇷Nîmes, France